Hostname: page-component-6bb9c88b65-kfd97 Total loading time: 0 Render date: 2025-07-23T03:05:03.568Z Has data issue: false hasContentIssue false
  • English
  • Français

PUFA, psoriasis and atherosclerotic CVD: evidence from the National Health and Nutrition Examination Survey database 2003–2006 and 2009–2014

Published online by Cambridge University Press:  19 May 2025

Yixuan Li  and
Xinghui Li Open the ORCID record for Xinghui Li [Opens in a new window]
Yixuan Li
Affiliation:
Department of Dermatology, Shidong Hospital of Yangpu District, Shanghai 200438, People’s Republic of China
Xinghui Li*
Affiliation:
The Yancheng Clinical College of Xuzhou Medical University, The First People’s Hospital of Yancheng Dermatology Department, Yancheng 224001, Jiangsu Province, People’s Republic of China
*
Corresponding author: Xinghui Li; Email: lxh15251105778@outlook.com
Get access Rights & Permissions [Opens in a new window]

Abstract

This study aimed to investigate the potential effect of PUFA intake on the association between psoriasis and 10-year atherosclerotic CVD (ASCVD) risk. Data of this study were extracted from the National Health and Nutrition Examination Survey database 2003–2006 and 2009–2014. The 10-year ASCVD risk score was calculated based on American College of Cardiology/American Heart Association guidelines, and the subjects were stratified into high 10-year ASCVD risk (≥ 7·5 %) and low 10-year ASCVD risk (< 7·5 %), accordingly. The weighted univariate and multivariate logistic regression models were utilised to evaluate the effect of total PUFA and its subtypes intake on the association between psoriasis and 10-year ASCVD risk. This effect was further evaluated in the subgroup of subjects aged ≥ 60 and < 60 years old. A total of 8705 participants were included, with 41·02 % (n 3571) in the high 10-year ASCVD risk (≥ 7·5 %). We observed subjects with psoriasis (OR 1·65; 95 % CI 1·02, 2·67) and low n-3 intake (OR 1·27; 95 % CI 1·025, 1·53) were associated with high 10-year ASCVD risk; no significant association was found between n-6 and 10-year ASCVD risk. The moderating effect of n-3 intake on the association between psoriasis and 10-year ASCVD risk was observed (OR 2·56; 95 % CI 1·04, 6·26). We also found among the n-3 components, α-linolenic acid (OR 2·72; 95 % CI 1·10, 6·70) had a more significant moderating effect on the association between psoriasis and 10-year ASCVD risk, especially in the subjects aged < 60 years (OR 2·41; 95 % CI 1·36, 4·28). Adequate intake of n-3, especially α-linolenic acid, may have potential benefits on improving cardiovascular health in psoriasis patients.

Keywords

PUFAn-3Psoriasis10-year atherosclerotic CVD riskNational Health and Nutrition Examination Survey database

Information

Type
Research Article
Information
British Journal of Nutrition , Volume 133 , Issue 10 , 28 May 2025 , pp. 1331 - 1341
Check for updates
Copyright
© The Author(s), 2025. Published by Cambridge University Press on behalf of The Nutrition Society

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Article purchase

Temporarily unavailable

References

Griffiths, CEM, Armstrong, AW, Gudjonsson, JE, et al. (2021) Psoriasis. Lancet 397, 1301–1315.CrossRefGoogle ScholarPubMed
Ruan, Z, Lu, T, Chen, Y, et al. (2022) Association between psoriasis and nonalcoholic fatty liver disease among outpatient US adults. JAMA Dermatol 158, 745–753.CrossRefGoogle ScholarPubMed
Knabel, M & Mudaliar, K (2022) Histopathologic features of inverse psoriasis. J Cutan Pathol 49, 246–251.CrossRefGoogle ScholarPubMed
Gao, N, Kong, M, Li, X, et al. (2022) The association between psoriasis and risk of cardiovascular disease: a Mendelian randomization analysis. Front Immunol 13, 918224.CrossRefGoogle ScholarPubMed
Hu, SC & Lan, CE (2017) Psoriasis and cardiovascular comorbidities: focusing on severe vascular events, cardiovascular risk factors and implications for treatment. Int J Mol Sci 18, 2211.CrossRefGoogle ScholarPubMed
Honda, T & Kabashima, K (2019) Current understanding of the role of dietary lipids in the pathophysiology of psoriasis. J Dermatol Sci 94, 314–320.CrossRefGoogle ScholarPubMed
Guida, B, Napoleone, A, Trio, R, et al. (2014) Energy-restricted, n-3 polyunsaturated fatty acids-rich diet improves the clinical response to immuno-modulating drugs in obese patients with plaque-type psoriasis: a randomized control clinical trial. Clin Nutr 33, 399–405.CrossRefGoogle ScholarPubMed
Wang, X, Ma, R, Shi, R, et al. (2023) Sex differences in the association between plasma polyunsaturated fatty acids levels and moderate-to-severe plaque psoriasis severity: a cross-sectional and longitudinal study. J Transl Med 21, 834.CrossRefGoogle ScholarPubMed
Upala, S, Yong, WC, Theparee, T, et al. (2017) Effect of n-3 fatty acids on disease severity in patients with psoriasis: a systematic review. Int J Rheum Dis 20, 442–450.CrossRefGoogle ScholarPubMed
Qin, S, Wen, J, Bai, XC, et al. (2014) Endogenous n-3 polyunsaturated fatty acids protect against imiquimod-induced psoriasis-like inflammation via the IL-17/IL-23 axis. Mol Med Rep 9, 2097–2104.CrossRefGoogle ScholarPubMed
Clark, CCT, Taghizadeh, M, Nahavandi, M, et al. (2019) Efficacy of ω-3 supplementation in patients with psoriasis: a meta-analysis of randomized controlled trials. Clin Rheumatol 38, 977–988.CrossRefGoogle ScholarPubMed
Phillips, CM, Chen, LW, Heude, B, et al. (2019) dietary inflammatory index and non-communicable disease risk: a narrative review. Nutrients 11, 1873.CrossRefGoogle ScholarPubMed
Elagizi, A, Lavie, CJ, O’Keefe, E, et al. (2021) An update on n-3 polyunsaturated fatty acids and cardiovascular health. Nutrients 13, 204.CrossRefGoogle Scholar
Borges, MC, Haycock, PC, Zheng, J, et al. (2022) Role of circulating polyunsaturated fatty acids on cardiovascular diseases risk: analysis using Mendelian randomization and fatty acid genetic association data from over 114 000 UK Biobank participants. BMC Med 20, 210.CrossRefGoogle ScholarPubMed
Jiang, H, Wang, L, Wang, D, et al. (2022) n-3 polyunsaturated fatty acid biomarkers and risk of type 2 diabetes, cardiovascular disease, cancer, and mortality. Clin Nutr 41, 1798–1807.CrossRefGoogle ScholarPubMed
Grundy, SM, Stone, NJ, Bailey, AL, et al. (2019) 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines. Circulation 139, e1082–e1143.Google Scholar
Jiang, S, Yang, W, Li, Y, et al. (2023) Monounsaturated and polyunsaturated fatty acids concerning prediabetes and type 2 diabetes mellitus risk among participants in the National Health and Nutrition Examination Surveys (NHANES) from 2005 to March 2020. Front Nutr 10, 1284800.CrossRefGoogle ScholarPubMed
Ahluwalia, N, Dwyer, J, Terry, A, et al. (2016) Update on NHANES dietary data: focus on collection, release, analytical considerations, and uses to inform public policy. Adv Nutr 7, 121–134.CrossRefGoogle ScholarPubMed
Mendes, MA, da Silva, I, Ramires, V, et al. (2018) Metabolic equivalent of task (METs) thresholds as an indicator of physical activity intensity. PLoS One 13, e0200701.CrossRefGoogle Scholar
Zhang, J, Chen, Y, Zou, L, et al. (2023) Prognostic nutritional index as a risk factor for diabetic kidney disease and mortality in patients with type 2 diabetes mellitus. Acta Diabetol 60, 235–245.CrossRefGoogle ScholarPubMed
Inker, LA & Titan, S (2021) Measurement and estimation of GFR for use in clinical practice: core curriculum 2021. Am J Kidney Dis 78, 736–749.CrossRefGoogle ScholarPubMed
Gelfand, JM, Troxel, AB, Lewis, JD, et al. (2007) The risk of mortality in patients with psoriasis: results from a population-based study. Arch Dermatol 143, 1493–1499.CrossRefGoogle ScholarPubMed
Reed, WB & Becker, SW (1960) Psoriasis and arthritis. Arch Dermatol 81, 577–585.CrossRefGoogle ScholarPubMed
McDonald, CJ & Calabresi, P (1978) Psoriasis and occlusive vascular disease. Br J Dermatol 99, 469–475.CrossRefGoogle ScholarPubMed
Friedewald, VE, Cather, JC, Gelfand, JM, et al. (2008) AJC editor’s consensus: psoriasis and coronary artery disease. Am J Cardiol 102, 1631–1643.CrossRefGoogle ScholarPubMed
Gelfand, JM, Neimann, AL, Shin, DB, et al. (2006) Risk of myocardial infarction in patients with psoriasis. JAMA 296, 1735–1741.CrossRefGoogle ScholarPubMed
Lai, YC & Yew, YW (2016) Psoriasis as an independent risk factor for cardiovascular disease: an epidemiologic analysis using a national database. J Cutan Med Surg 20, 327–333.CrossRefGoogle Scholar
Kan, J, Chen, Q, Tao, Q, et al. (2024) Prospective evaluation of cardiovascular risk and mortality in patients with psoriasis: an American population-based study. Exp Dermatol 33, e15010.CrossRefGoogle ScholarPubMed
Libby, P (2012) Inflammation in atherosclerosis. Arterioscler Thromb Vasc Biol 32, 2045–2051.CrossRefGoogle ScholarPubMed
Garshick, MS, Barrett, TJ, Wechter, T, et al. (2019) Inflammasome signaling and impaired vascular health in psoriasis. Arterioscler Thromb Vasc Biol 39, 787–798.CrossRefGoogle ScholarPubMed
Greb, JE, Goldminz, AM, Elder, JT, et al. (2016) Psoriasis. Nat Rev Dis Primers 2, 16082.CrossRefGoogle ScholarPubMed
Teague, HL, Aksentijevich, M, Stansky, E, et al. (2020) Cells of myeloid origin partly mediate the association between psoriasis severity and coronary plaque. J Invest Dermatol 140, 912–915.e911.CrossRefGoogle ScholarPubMed
Bowman, L, Mafham, M, Wallendszus, K, et al. (2018) Effects of n-3 fatty acid supplements in diabetes mellitus. N Engl J Med 379, 1540–1550.Google ScholarPubMed
Manson, JE, Cook, NR, Lee, IM, et al. (2019) Marine n-3 fatty acids and prevention of cardiovascular disease and cancer. N Engl J Med 380, 23–32.CrossRefGoogle ScholarPubMed
Bhatt, DL, Miller, M, Brinton, EA, et al. (2020) REDUCE-IT USA: results from the 3146 patients randomized in the United States. Circulation 141, 367–375.CrossRefGoogle ScholarPubMed
Bernasconi, AA, Wiest, MM, Lavie, CJ, et al. (2021) Effect of n-3 dosage on cardiovascular outcomes: an updated meta-analysis and meta-regression of interventional trials. Mayo Clin Proc 96, 304–313.CrossRefGoogle Scholar
Li, J, Shen, Q, Guo, C, et al. (2024) Causality of unsaturated fatty acids and psoriasis a Mendelian randomization study. Front Nutr 11, 1280962.CrossRefGoogle ScholarPubMed
Morin, S, Simard, M, Rioux, G, et al. (2022) Alpha-linolenic acid modulates T cell incorporation in a 3D tissue-engineered psoriatic skin model. Cells 11, 1513.CrossRefGoogle Scholar
Backes, J, Anzalone, D, Hilleman, D, et al. (2016) The clinical relevance of n-3 fatty acids in the management of hypertriglyceridemia. Lipids Health Dis 15, 118.CrossRefGoogle ScholarPubMed
Sheikh, O, Vande Hei, AG, Battisha, A, et al. (2019) Cardiovascular, electrophysiologic, and hematologic effects of n-3 fatty acids beyond reducing hypertriglyceridemia: as it pertains to the recently published REDUCE-IT trial. Cardiovasc Diabetol 18, 84.CrossRefGoogle Scholar
Plissonneau, C, Capel, F, Chassaing, B, et al. (2021) High-intensity interval training and α-linolenic acid supplementation improve DHA conversion and increase the abundance of gut mucosa-associated Oscillospira bacteria. Nutrients 13, 788.CrossRefGoogle ScholarPubMed
Supplementary material: File

Li and Li supplementary material

Li and Li supplementary material
Download Li and Li supplementary material(File)
File 44 KB